Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

ConclusionAdjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1  year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research